Expert Interviews

Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.

CancerNetwork® sat down with Conor E. Steuer, MD, to discuss a recently published prospective study which found a high rate of smoking reduction and cessation in patients with non–small cell lung cancer.

CancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.

Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

During Colorectal Cancer Awareness month, CancerNetwork® sat down with Dorothy Dulko, PhD, to discuss social determinants of cancer.

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.

The medical oncologist at Memorial Sloan Kettering Cancer Center highlighted what clinicians treating patients with advanced ccRCC should understand about this trial in progress.

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

CancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.